Through Nov. 15 of last year, pharma deal value rose 79% compared to the same period in 2024, according to Bain. The average deal size also climbed more than 80%, “signaling a decisive return of ...
Artificial intelligence has yet to deliver on the most challenging aspect of drug development -- finding new molecules that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results